What is the address of PGL PHARMA?

The registered office of PGL PHARMA is located at Deigné 90, 4920 Aywaille.

Is PGL PHARMA still active?

Yes. According to the CBE (29 October 2026) PGL PHARMA is active, legal situation “Normale toestand”, started on 3 March 2021.

Is PGL PHARMA registered on Peppol?

Yes, PGL PHARMA is registered on the Peppol network with ID 0208:0764558948.

What is the enterprise number of PGL PHARMA?

The enterprise number of PGL PHARMA is BE0764558948.

When was PGL PHARMA founded?

PGL PHARMA was founded on 3 March 2021.

Who are the directors of PGL PHARMA?

According to the 2025 annual accounts, the directors of PGL PHARMA are: GOFFIN F.R. MANAGEMENT SRL, LEROY FRAITURE GESTION SRL, Nicolas PUTOIS SRL.

Is PGL PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 March 2021; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PGL PHARMA make in 2025?

PGL PHARMA posted a profit after taxes of € 47,372 in financial year 2025.

What is the revenue of PGL PHARMA?

As a small company, PGL PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 69,333.

PGL PHARMA (Private Limited) - Aywaille - BE0764558948

Q: What does PGL PHARMA do?

PGL PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 3 March 2021, 1 establishment.

Dossier PGL PHARMA, printed on 29 October 2026 from databakkes.be/en/0764558948/pgl-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PGL PHARMA from Aywaille, company number BE0764558948, closed financial year 2025 with a result of € 47,372 after tax. For that financial year PGL PHARMA recorded a gross margin of € 69,333 and equity of € 226,332. Compared with financial year 2024, the result moved from € -188,790 to € 47,372. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Growing

€ 226,332

▲ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 47,372

▲ still € 188,790 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 5,956

▼ 74% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 181,332.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 411,667

▼ 14% vs 2024

€ 70,417 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 1,487

▼ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 7,314

▼ 75% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 72,574 Gross margin 2022: € 72,574 First fiscal year in the series	€ 112,074 Gross margin 2023: € 112,074 ▲ 54% vs 2022 (€ 72,574) Favourable step	€ 83,165 Gross margin 2024: € 83,165 ▼ 26% vs 2023 (€ 112,074) Unfavourable step	€ 69,333 Gross margin 2025: € 69,333 ▼ 17% vs 2024 (€ 83,165) Unfavourable step	▼ 17%
Profit after taxes	€ 117,535 Profit after taxes 2022: € 117,535 First fiscal year in the series	€ 205,215 Profit after taxes 2023: € 205,215 ▲ 75% vs 2022 (€ 117,535) Favourable step	€ -188,790 Profit after taxes 2024: € -188,790 ▼ € 394,005 vs 2023 (€ 205,215) Unfavourable step	€ 47,372 Profit after taxes 2025: € 47,372 ▲ € 236,161 vs 2024 (€ -188,790) Favourable step	▲ € 236,161
Equity	€ 162,535 Equity 2022: € 162,535 First fiscal year in the series	€ 367,750 Equity 2023: € 367,750 ▲ 126% vs 2022 (€ 162,535) Favourable step	€ 178,960 Equity 2024: € 178,960 ▼ 51% vs 2023 (€ 367,750) Unfavourable step	€ 226,332 Equity 2025: € 226,332 ▲ 26% vs 2024 (€ 178,960) Favourable step	▲ 26%
Total debts	€ 1,956,452 Total debts 2022: € 1,956,452 First fiscal year in the series	€ 1,698,365 Total debts 2023: € 1,698,365 ▼ 13% vs 2022 (€ 1,956,452) Favourable step	€ 782,449 Total debts 2024: € 782,449 ▼ 54% vs 2023 (€ 1,698,365) Favourable step	€ 744,025 Total debts 2025: € 744,025 ▼ 5% vs 2024 (€ 782,449) Favourable step	▼ 5%
Cash	€ 55,090 Cash 2022: € 55,090 First fiscal year in the series	€ 6,680 Cash 2023: € 6,680 ▼ 88% vs 2022 (€ 55,090) Unfavourable step	€ 23,033 Cash 2024: € 23,033 ▲ 245% vs 2023 (€ 6,680) Favourable step	€ 5,956 Cash 2025: € 5,956 ▼ 74% vs 2024 (€ 23,033) Unfavourable step	▼ 74%
Retained profit	€ 117,535 Retained profit 2022: € 117,535 First fiscal year in the series	€ 322,750 Retained profit 2023: € 322,750 ▲ 175% vs 2022 (€ 117,535) Favourable step	€ 133,960 Retained profit 2024: € 133,960 ▼ 58% vs 2023 (€ 322,750) Unfavourable step	€ 181,332 Retained profit 2025: € 181,332 ▲ 35% vs 2024 (€ 133,960) Favourable step	▲ 35%
Bank debt	€ 1,622,500 Bank debt 2022: € 1,622,500 First fiscal year in the series	€ 1,245,500 Bank debt 2023: € 1,245,500 ▼ 23% vs 2022 (€ 1,622,500) Favourable step	€ 476,667 Bank debt 2024: € 476,667 ▼ 62% vs 2023 (€ 1,245,500) Favourable step	€ 411,667 Bank debt 2025: € 411,667 ▼ 14% vs 2024 (€ 476,667) Favourable step	▼ 14%
Balance sheet total	€ 2,118,987 Balance sheet total 2022: € 2,118,987 First fiscal year in the series	€ 2,066,114 Balance sheet total 2023: € 2,066,114 ▼ 2% vs 2022 (€ 2,118,987) Unchanged	€ 961,410 Balance sheet total 2024: € 961,410 ▼ 53% vs 2023 (€ 2,066,114) Unchanged	€ 970,357 Balance sheet total 2025: € 970,357 ▲ 1% vs 2024 (€ 961,410) Unchanged	▲ 1%

Key figures of PGL PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PGL PHARMA?

What happened at PGL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: profit of € 47,372. Source: NBB ↗
Mar 3, 2021 New establishment in Aywaille. KBO
Mar 3, 2021 Start of the company according to the CBE. KBO

In short

From € 117,535 profit in 2022 to € 47,372 profit in 2025.

Paid € 51,801 in corporate taxes since 2022.

Best year ever: 2023, with € 205,215 profit.

Original PDFs at the National Bank ↗

Management

GOFFIN F.R. MANAGEMENT

LEROY FRAITURE GESTION

Nicolas PUTOIS

The stake of GOFFIN F.R. MANAGEMENT, LEROY FRAITURE GESTION, Nicolas PUTOIS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PGL PHARMA

Pharmacie de Bois de Breux 100%

Pharmacie Thier à Liège 100%

Behind PGL PHARMA are GOFFIN F.R. MANAGEMENT SRL, LEROY FRAITURE GESTION SRL and Nicolas PUTOIS SRL. The shares are held by GOFFIN F.R. MANAGEMENT, LEROY FRAITURE GESTION and Nicolas PUTOIS. It owns 100% of Pharmacie de Bois de Breux and 100% of Pharmacie Thier à Liège itself.